Another Study Points to Yaz, Yasmin DangersNov 8, 2011 | Parker Waichman LLP
For the third time in just a few weeks, a study is confirming a higher risk of blood clots among women who use birth control pills like Yaz or Yasmin. According to the new study, the increased blood clot risk associated with Yaz, Yasmin and other pills made with the progestin, drospirenone, would translate to about eight to 10 clots per 10,000 women per year.
The new study is published in the Canadian Medical Association Journal, and involved more than 300,000 women in Israel, found that women who took pills made with drospirenone, including Yaz or Yasmin, faced a 43 percent to 65 percent higher risk of suffering a type of blood clot called venous thromboembolism (VTE). According to the article, the VTE risk associated with such birth control pills increased with age.
This new study is just the latest to point to dangers associated with Yaz and Yasmin. At the end of last month, the U.S. Food & Drug Administration (FDA) announced that a study it commissioned had found women taking Yaz, Yasmin and other pills made drospirenone had a 75 percent greater chance of experiencing VTE compared to those using pills made with levonorgestrel. Just prior to the FDA announcement, a separate study published in the British Medical Journal found drospirenone and other new-generation progestins double the risk of blood clots compared to levonorgestrel.
The FDA has scheduled a joint meeting of the Reproductive Health Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee for December 8 to discuss the safety of drospirenone birth control pills.